619 related articles for article (PubMed ID: 18602955)
1. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
Pákáski M; Kálmán J
Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
[TBL] [Abstract][Full Text] [Related]
2. Muscarinic agonists as preventative therapy for Alzheimer's disease.
Beach TG
Curr Opin Investig Drugs; 2002 Nov; 3(11):1633-6. PubMed ID: 12476965
[TBL] [Abstract][Full Text] [Related]
3. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
4. The role of nicotinic acetylcholine receptors in Alzheimer's disease.
Oddo S; LaFerla FM
J Physiol Paris; 2006; 99(2-3):172-9. PubMed ID: 16448808
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of cholinergic dysfunction and cognitive deficits induced by amyloid beta-peptide.
Tran MH; Yamada K; Nabeshima T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2001 Oct; 21(4):125-32. PubMed ID: 11769570
[TBL] [Abstract][Full Text] [Related]
6. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease.
Fuentealba RA; Farias G; Scheu J; Bronfman M; Marzolo MP; Inestrosa NC
Brain Res Brain Res Rev; 2004 Dec; 47(1-3):275-89. PubMed ID: 15572177
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease.
Wu CK; Thal L; Pizzo D; Hansen L; Masliah E; Geula C
Exp Neurol; 2005 Oct; 195(2):484-96. PubMed ID: 16085017
[TBL] [Abstract][Full Text] [Related]
8. Neuronal nicotinic acetylcholine receptors serve as sensitive targets that mediate beta-amyloid neurotoxicity.
Liu Q; Wu J
Acta Pharmacol Sin; 2006 Oct; 27(10):1277-86. PubMed ID: 17007734
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology.
Silvestrelli G; Lanari A; Parnetti L; Tomassoni D; Amenta F
Mech Ageing Dev; 2006 Feb; 127(2):148-57. PubMed ID: 16278007
[TBL] [Abstract][Full Text] [Related]
10. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering?
Davis RE; Doyle PD; Carroll RT; Emmerling MR; Jaen J
Arzneimittelforschung; 1995 Mar; 45(3A):425-31. PubMed ID: 7763338
[TBL] [Abstract][Full Text] [Related]
11. [Amyloid cascade hypothesis of Alzheimer's disease and alpha 7 nicotinic receptor].
Hashimoto K; Iyo M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Apr; 22(2):49-53. PubMed ID: 12050852
[TBL] [Abstract][Full Text] [Related]
12. [Neurotransmitters in Alzheimer's disease].
Manzano-Palomo S; De la Morena-Vicente MA; Barquero MS
Rev Neurol; 2006 Mar 16-31; 42(6):350-3. PubMed ID: 16575771
[TBL] [Abstract][Full Text] [Related]
13. Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease.
Verhoeff NP
Expert Rev Neurother; 2005 Mar; 5(2):277-84. PubMed ID: 15853497
[TBL] [Abstract][Full Text] [Related]
14. The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease.
Coulson EJ; May LM; Sykes AM; Hamlin AS
Neuroscientist; 2009 Aug; 15(4):317-23. PubMed ID: 19458382
[TBL] [Abstract][Full Text] [Related]
15. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
Wang YJ; Zhou HD; Zhou XF
Drug Discov Today; 2006 Oct; 11(19-20):931-8. PubMed ID: 16997144
[TBL] [Abstract][Full Text] [Related]
16. Cholinergic function and Alzheimer's disease.
Giacobini E
Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S1-5. PubMed ID: 12973744
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of synaptic dysfunction in Alzheimer's disease.
Masliah E
Histol Histopathol; 1995 Apr; 10(2):509-19. PubMed ID: 7599445
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease.
Nordberg A
Alzheimer Dis Assoc Disord; 2006; 20(2 Suppl 1):S12-8. PubMed ID: 16772751
[TBL] [Abstract][Full Text] [Related]
19. Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease.
Lai MK; Tsang SW; Garcia-Alloza M; Minger SL; Nicoll JA; Esiri MM; Wong PT; Chen CP; Ramírez MJ; Francis PT
Neurobiol Dis; 2006 Jun; 22(3):555-61. PubMed ID: 16473016
[TBL] [Abstract][Full Text] [Related]
20. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.
Terry AV; Buccafusco JJ
J Pharmacol Exp Ther; 2003 Sep; 306(3):821-7. PubMed ID: 12805474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
